title: Rapid induction of clinical response with a short-term high-dose starting schedule of budesonide nebulizing suspension in young children with recurrent wheezing episodes.
abstract: BACKGROUND
  There are no data currently available on the correct schedule for the initiation of treatment with nebulized suspension of budesonide in children with recurrent wheezing episodes. We compared the efficacy and safety of starting with a high dose followed by a stepwise decrease to a continuous low dose.
  
  
  METHODS
  In a double-blind design, 42 children aged 6 months to 3 years were randomly allocated to receive either a high starting dose of 1 mg budesonide twice daily followed by a stepwise decrease of 25% every second day for 1 week (group A) or a low dose of 0.25 mg twice daily for 1 week (group B). Efficacy was assessed with daily symptom scores and the systemic effect of the corticosteroids with the adrenocorticotropic hormone test.
  
  
  RESULTS
  The two groups were comparable for all parameters evaluated. During the first week of treatment, there was a significant decrease in asthmatic symptomatology only in group A: a 59% decrease for wheezing (p = 0.0001), 39% for diurnal cough (p = 0.036), and 39% for nocturnal cough (p = 0.04). Mean time to clinical response was 3.0 days in group A and 5.7 days in group B (p = 0.02). This early improvement was sustained for the rest of the follow-up period. The high dose starting schedule was not associated with any change in serum cortisol level.
  
  
  CONCLUSIONS
  The administration of nebulized suspension of budesonide at a high starting dose schedule followed by a rapid (1 week) stepwise decrease yields a significant early improvement in asthma symptoms and causes no change in serum cortisol levels.
authors.affiliation: Department of Pediatrics C, Schneider Children's Medical Center of Israel, Petah Tikva.
authors.forename: B
authors.initials: B
authors.lastname: Volovitz
authors.forename: R
authors.initials: R
authors.lastname: Soferman
authors.forename: H
authors.initials: H
authors.lastname: Blau
authors.forename: M
authors.initials: M
authors.lastname: Nussinovitch
authors.forename: I
authors.initials: I
authors.lastname: Varsano
mesh_terms: D000280:Administration, Inhalation; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy*; D019819:Budesonide / Q000008:administration & dosage*; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D012008:Recurrence; D012135:Respiratory Sounds / Q000187:drug effects*; D013535:Suspensions
chemical_list: D000893:Anti-Inflammatory Agents; D013535:Suspensions; D019819:Budesonide